Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

D I Stirling

Showing results (21-30 of 25) with videos related to

Pageof 3
Sort By:
You have reached the last page of results.This site can display upto 25 results.
British Journal of Cancer|March 5, 2004
Phase I study to determine the safety, tolerability and immunostimulatory activity of thalidomide analogue CC-5013 in patients with metastatic malignant melanoma and other advanced cancersJ B Bartlett, A Michael, I A Clarke, et al.
Blood|October 26, 2000
Thalidomide and its analogs overcome drug resistance of human multiple myeloma cells to conventional therapyT Hideshima, D Chauhan, Y Shima, et al.
British Journal of Pharmacology|January 7, 2010
Apremilast, a cAMP phosphodiesterase-4 inhibitor, demonstrates anti-inflammatory activity in vitro and in a model of psoriasisP H Schafer, A Parton, A K Gandhi, et al.
Leukemia|December 26, 2001
Adherence of multiple myeloma cells to bone marrow stromal cells upregulates vascular endothelial growth factor secretion: therapeutic applicationsD Gupta, S P Treon, Y Shima, et al.
Blood|June 22, 2001
Thalidomide and immunomodulatory derivatives augment natural killer cell cytotoxicity in multiple myelomaF E Davies, N Raje, T Hideshima, et al.
Pageof 3

Showing results (21-30 of 25) with videos related to

Sort By:
Pageof 3
You have reached the last page of results.This site can display upto 25 results.
British Journal of Cancer|March 5, 2004
Phase I study to determine the safety, tolerability and immunostimulatory activity of thalidomide analogue CC-5013 in patients with metastatic malignant melanoma and other advanced cancersJ B Bartlett, A Michael, I A Clarke, et al.
Blood|October 26, 2000
Thalidomide and its analogs overcome drug resistance of human multiple myeloma cells to conventional therapyT Hideshima, D Chauhan, Y Shima, et al.
British Journal of Pharmacology|January 7, 2010
Apremilast, a cAMP phosphodiesterase-4 inhibitor, demonstrates anti-inflammatory activity in vitro and in a model of psoriasisP H Schafer, A Parton, A K Gandhi, et al.
Leukemia|December 26, 2001
Adherence of multiple myeloma cells to bone marrow stromal cells upregulates vascular endothelial growth factor secretion: therapeutic applicationsD Gupta, S P Treon, Y Shima, et al.
Blood|June 22, 2001
Thalidomide and immunomodulatory derivatives augment natural killer cell cytotoxicity in multiple myelomaF E Davies, N Raje, T Hideshima, et al.
Pageof 3